CHMFL-EGFR-202

Overview

CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor ( EGFR ) mutant kinase , with IC 50 s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ～10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR , with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines.

Application

Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > EGFR | Products > Signaling Pathways > BMX Kinase | Products > Signaling Pathways > Btk | Products > Signaling Pathways > MEK

Product Information

• Catalog No.: HY-101522
• CAS No.: 2089381-40-6
• Molecular Formula: C25H24ClN7O2
• Molecular Weight: 489.96
• Purity: 99.75%
• Storage: -20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Solubility: ≥ 2.75 mg/mL (5.61 mM); Clear solution
• Availability: In-stock

Source

Original product source